An interventional study of BCAA and Leucine in Muscle Damage and Inflammation, sponsored by University of Sao Paulo. Suspended at 1 site in Brazil. Open to male participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-05-05.
Sponsored by University of Sao Paulo · Not applicable, Interventional, and Treatment
This study aims to evaluate the effects of branched-chain amino acids (BCAA) supplementation on resistance exercise-induced muscle damage and inflammation.
3,439 studies on the registry are indexed under Inflammation; 629 are open to participants now.
This study's planned enrollment of 30 is below the median of 50 across 2,437 interventional studies indexed under Inflammation.
Browse Inflammation studies →University of Sao Paulo is the lead sponsor of 1,005 studies on the registry; 90 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Dietary Supplement: BCAA
Dietary Supplement: Leucine
Dietary Supplement: Placebo
7 g of leucine + 3,5 g of isoleucine + 3,5 g of valine per day during 9 days
7 g of leucine + 7 g of alanine per day during 9 days
14 g of alanine per day during 9 days
Muscle maximal strength
Time frame: 4 days
Muscle edema
Time frame: 4 days
Muscle soreness
Time frame: 4 days
Muscle inflammation
Immunohistochemistry, protein expression.
Time frame: 4 days
Muscle damage
Serum creatine kinase
Time frame: 4 days
This study is suspended, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Sao Paulo